Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cellular RNA substrates susceptible to off-target adenine deamination refer to the vast array of RNA molecules unintentionally modified by Adenine Base Editors (ABEs). ABEs typically employ a laboratory-evolved TadA (tRNA-specific adenosine deaminase) domain from Escherichia coli, fused to a CRISPR-Cas protein, to perform targeted A-to-G transitions in genomic DNA (Gaudelli et al., 2017). However, studies have revealed that the TadA domain retains an inherent affinity for RNA, leading to extensive, guide-independent A-to-I (adenosine-to-inosine) deamination across the transcriptome (Grünewald et al., 2019; Rees et al., 2019). Because inosine is recognized as guanosine by the cellular translation machinery, these off-target events can result in the synthesis of synonymous or non-synonymous protein variants, potentially causing cellular toxicity or functional impairment. While RNA editing is transient and does not permanently alter the genome, the high frequency and breadth of these modifications present a significant safety hurdle for the clinical translation of base editing therapies. Consequently, next-generation ABEs are being engineered with specific mutations in the TadA domain to minimize RNA binding while maintaining high DNA editing efficiency.
Hydrolytic deamination of adenosine to inosine in RNA transcripts, which is read as guanosine by the translation machinery.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cellular RNA substrates susceptible to off-target adenine deamination by the TadA deaminase domain (RNA off-targets of ABE).